Coherus announces positive Phase III results for Humira biosimilar candidate

January 20, 2017 6:01 PM

Coherus BioSciences, Inc., reported results from an ongoing 3-Part, Phase 3 clinical study of CHS-1420, an adalimumab (Humira) biosimilar candidate.

This study met its primary endpoint demonstrating similarity between CHS-1420 and Humira with respect to percentage of subjects achieving 75% improvement in psoriasis area and severity index (PASI-75) at week 12.  The 95% confidence intervals for the difference between treatment groups fell well within the pre-specified margin.

Results from Part 2 of the study focused on maintenance of response through Week 24.  At the start of Part 2 (Week 16), 80.3% of subjects in the CHS-1420 group and 77.5% of subjects in the Humira group achieved PASI-75.  In Part 2 (weeks 16-24), half of the subjects who were initially treated with Humira were switched to CHS-1420, modeling a chronic patient’s transition to a biosimilar.  In Part 2, maintenance of PASI-75 was similar across the 3 subsequent treatment groups: CHS-1420 followed by CHS-1420, Humira followed by CHS-1420, and Humira followed by Humira. CHS-1420 and Humira were similarly well tolerated in all groups during Part 2. Anti-drug antibody results are preliminary at this time, but have not identified any clinically significant differences between the treatment groups.

This is a confirmatory, randomized, double-blind, active-control, parallel-group, 3-part study in patients with active, moderate to severe, chronic plaque psoriasis.  In Part 3, all subjects receive CHS-1420 for an additional 24 weeks.  Data from this study will be presented at an upcoming scientific conference.

The company currently anticipates filing the Biologic License Application (BLA) submission in the first half of 2017.

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)

Latest News on Biosimilar News

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?


Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!